Arshad M. Khanani, MD, MA, FASRS
Show Description +
Dr. Khanani explains the results of a fellow-eye bilateral dosing study of investigational ABBV-RGX-314 (Regenxbio/Abbvie) gene therapy for wet AMD. Subretinal delivery of the drug led to a 97% reduction in anti-VEGF treatment burden at 9 months.
Posted: 10/22/2024
Arshad M. Khanani, MD, MA, FASRS
Dr. Khanani explains the results of a fellow-eye bilateral dosing study of investigational ABBV-RGX-314 (Regenxbio/Abbvie) gene therapy for wet AMD. Subretinal delivery of the drug led to a 97% reduction in anti-VEGF treatment burden at 9 months.
Posted: 10/22/2024
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2024.
Please log in to leave a comment.